Olaparib
Phase 2TerminatedDevelopment Stage
Prostate Adenocarcinoma Without Neuroendocrine Differentiation
Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Sep 11, 2018 → Jul 3, 2019
About Olaparib
Olaparib is a phase 2 stage product being developed by AstraZeneca for Prostate Adenocarcinoma Without Neuroendocrine Differentiation. The current trial status is terminated. This product is registered under clinical trial identifier NCT03570476. Target conditions include Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8.
Hype Score Breakdown
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03063710 | Pre-clinical | Completed |
| NCT05501548 | Phase 2 | Terminated |
| NCT04951492 | Phase 2 | Terminated |
| NCT05482074 | Phase 2 | Withdrawn |
| NCT05262608 | Phase 2 | UNKNOWN |
| NCT04884360 | Phase 3 | Active |
| NCT04515836 | Phase 2 | Recruiting |
| NCT04532645 | Pre-clinical | Completed |
| NCT04421963 | Phase 3 | Active |
| NCT04330040 | Approved | Completed |
| NCT04236414 | Phase 1 | Completed |
| NCT03782818 | Phase 1/2 | Terminated |
| NCT03829345 | Phase 2 | UNKNOWN |
| NCT03786796 | Phase 2 | Recruiting |
| NCT03955640 | Phase 1 | Terminated |
| NCT03742895 | Phase 2 | Active |
| NCT04152941 | Pre-clinical | Completed |
| NCT03570476 | Phase 2 | Terminated |
| NCT03470805 | Phase 2 | Completed |
| NCT03448718 | Phase 2 | Completed |
Competing Products
20 competing products in Prostate Adenocarcinoma Without Neuroendocrine Differentiation